3-(nitrooxy)-2-((nitrooxy)methyl)propyl 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl)methyl)sulfinyl)benzimidazolecarboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 3-(nitrooxy)-2-((nitrooxy)methyl)propyl 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl)methyl)sulfinyl)benzimidazolecarboxylate
• 英文别名: [3-Nitrooxy-2-(nitrooxymethyl)propyl] 2-[[3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]benzimidazole-2-carboxylate
• 化学式: C₂₁H₂₀F₃N₅O₁₀S
• 分子量: 591.479
• InChiKey: WSIFXUFSVHUXRF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  40
• 可旋转键数：
  13
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  220
• 氢给体数：
  0
• 氢受体数：
  17

反应信息

• 作为产物：
  描述：

  3-(nitrooxy)-2-((nitrooxy)methyl)propan-1-chloroformate 、 兰索拉唑 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 2.25h， 以75%的产率得到3-(nitrooxy)-2-((nitrooxy)methyl)propyl 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl)methyl)sulfinyl)benzimidazolecarboxylate
  参考文献：
  名称：

  Nitrosated proton pump inhibitors, compositions and methods of use

  摘要：

  该发明描述了新颖的亚硝化质子泵抑制剂化合物及其药用盐，以及包含至少一种亚硝化质子泵抑制剂化合物的新型组合物，以及可选地，至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮源性舒张因子水平或是一氧化氮合酶底物的化合物，和/或至少一种治疗剂。该发明还提供了包含至少一种亚硝化质子泵抑制剂化合物和至少一种捐赠、转移或释放一氧化氮、提高内源性内皮源性舒张因子水平、刺激内源性一氧化氮合成或是一氧化氮合酶底物和/或至少一种治疗剂的新型组合物。该发明还提供了包含至少一种亚硝化质子泵抑制剂化合物，可选地至少一种一氧化氮供体和/或至少一种治疗剂的新型套装。该发明还提供了治疗胃肠道疾病的方法；促进溃疡愈合；减少溃疡复发；改善质子泵抑制剂的胃保护性能、抗幽门螺杆菌性能或抗酸性能；减少或减轻与非甾体类抗炎化合物使用相关的胃肠毒性；治疗细菌感染和/或病毒感染。

  公开号：

  US20040024014A1

文献信息

• NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE
  申请人：Nitromed, Inc.

  公开号：EP1534278A2

  公开（公告）日：2005-06-01
• EP1534278A4
  申请人：——

  公开号：EP1534278A4

  公开（公告）日：2006-09-06
• JP2005539013A
  申请人：——

  公开号：JP2005539013A

  公开（公告）日：2005-12-22
• US7211590B2
  申请人：——

  公开号：US7211590B2

  公开（公告）日：2007-05-01
• [EN] NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE<br/>[FR] INHIBITEURS NITROSES DE LA POMPE A PROTONS, COMPOSITIONS ET PROCEDES D'UTILISATION
  申请人：NITROMED INC

  公开号：WO2004012659A2

  公开（公告）日：2004-02-12

  The invention describes novel nitrosated proton pump inhibitor compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated proton pump inhibitor compound, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated proton pump inhibitor compound, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti-Helicobacter pylori properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating bacterial infections and/or viral infections.